Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
STAT+
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Pharma
STAT+

Doubling the user fee for FDA drug review draws blowback

By Sheila Kaplan March 16, 2017

Reprints
FDA Campus
FDA

WASHINGTON — Can the president who calls himself “the great negotiator” win over the other side after they’ve left the table?

According to President Trump’s budget, released today, that’s the plan.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Sheila Kaplan

Senior Writer, Washington

Sheila Kaplan is a senior writer for STAT, covering the intersection of science, money, and politics.

Tags

Watch: P-value, an important measurement in clinical trials, explained
Watch: P-value, an important measurement in clinical trials, explained
‘I’m terrified’: Patients scramble for treatment after 13 ketamine…
‘I’m terrified’: Patients scramble for treatment after 13 ketamine clinics shut down
Experts weigh in on potential health hazards posed by…
Experts weigh in on potential health hazards posed by chemicals in Ohio train derailment
Pharmalittle: Manufacturers say bird flu shots for humans can…
Pharmalittle: Manufacturers say bird flu shots for humans can be made quickly; obesity guidelines for children…
‘We’re getting much more aggressive’: Microsoft’s Nuance adds GPT-4…
‘We’re getting much more aggressive’: Microsoft’s Nuance adds GPT-4 AI to its medical note-taking tool
Karuna’s treatment for schizophrenia achieves study goals, bolsters FDA…
Karuna’s treatment for schizophrenia achieves study goals, bolsters FDA filing plans

Recommended Stories